Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF+ Melanoma

Jason M. Broderick @jasoncology
Published: Friday, Dec 22, 2017

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology

Samit Hirawat
The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of dabrafenib (Tafinlar) combined with trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x